ALX Oncology
San Francisco
About ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-╬▒ (SIRP╬▒) that have been engineered to bind CD47 with significantly greater affinity than natural SIRP╬▒.1.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $479.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:ALXO
- Website: alxoncology.com
- Phone: (353) 161-8000
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/alx-oncology-115651 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.